The Tau Pipeline Enabling Program (T-PEP)

The Tau Pipeline Enabling Program (T-PEP) seeks to accelerate the discovery of potential new therapies for tauopathies. The intent of this program is to enrich the pipeline for therapy development by facilitating the translation of academia derived ideas into practical application. In short, it bridges the gap between innovative but resource-constrained researchers and the larger pharmaceutical companies that are looking for drug candidates to be taken into human trials.

Program Overview:
The overarching goal of T-PEP is to promote the advanced study of a wide range of novel targets, agents and/or therapeutic strategies that will accelerate the development of disease modifying interventions for tauopathies.

Proposals responding to this program may focus on the toxicity of tau directly and/or they may target their studies on potential neurobiological mechanisms that promote or synergize tau formation or toxicity, e.g. calcium dyshomeostatis, mitochondrial dysfunction, neuroinflammation, microtubule stability (or instability) and function, axon transport, synapse dysfunction/loss, and other tau-related mechanisms. Applications addressing related mechanisms must include the rationale that it will prevent, reduce, remove or otherwise mitigate the toxic effects of tau build-up. Funds awarded under this program may be used for one or more steps in the drug discovery pipeline, including but not limited to i) lead discovery and optimization, ii) target validation and iii) IND-enabling studies, including cGMP scale-up/manufacture and animal efficacy studies.

T-PEP is open to researchers at academic institutions as well as small companies. There is no strict cut-off for company size, but preference will be given to companies with 50 or fewer employees.

For full details visit

Key Dates:

LOI is now open
LOI Deadline: February 23, 2022, 5:00 PM ET
Application Deadline for those invited to submit a full proposal: June 1, 2022, 5:00 PM ET
Award Notification: September 30, 2022

Visit funding web page

Translate »